• Inventiva appointed Axel-Sven Malkomes as chief financial officer ahead of expected top-line Phase 3 NATiV3 data for lanifibranor in Q4 2026.
• Malkomes was most recently CFO at CureVac, following CFO roles at Cardior and Medigene.
• Susan Coles joined as chief legal officer, coming from Vivet Therapeutics where she led legal and finance.
• Pamela Herbster joined as chief people officer, most recently leading human resources and business operations at Sage Therapeutics.
• Jean Volatier will move from CFO to EVP finance and corporate social responsibility.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inventiva SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604221600OMX_____CNEWS_EN_GNW1001177395_en) on April 22, 2026, and is solely responsible for the information contained therein.